首页> 美国卫生研究院文献>Internal Medicine >Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion
【2h】

Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion

机译:成功的自体造血干细胞移植继之以硼替佐米维持治疗的复发性CD138低的多发性孤立性浆细胞瘤患者其17p缺失

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Solitary bone plasmacytoma (SBP) tends to progress to multiple myeloma (MM); however, progression to multiple solitary plasmacytomas (MSP) is rare. We report a case of CD138-low MSP with 17p deletion in a patient with relapsed SBP. 17p deletion is associated with a poor outcome in patients with MM, and the low expression of CD138 in myeloma cells is associated with drug resistance and a poor prognosis. The patient was successfully treated with bortezomib plus dexamethasone induction therapy and autologous hematopoietic stem cell transplantation followed by bortezomib maintenance therapy. Consequently, bortezomib treatment was stopped and a stringent complete response has been maintained.
机译:孤立性骨浆细胞瘤(SBP)倾向于发展为多发性骨髓瘤(MM);然而,进展为多发性孤立性浆细胞瘤(MSP)的情况很少。我们报道一例SBP复发患者中CD138低的MSP伴17p缺失。 MM患者17p缺失与预后不良有关,骨髓瘤细胞CD138的低表达与耐药性及预后不良有关。该患者成功接受了硼替佐米联合地塞米松诱导治疗和自体造血干细胞移植,随后进行了硼替佐米维持治疗。因此,停止了硼替佐米的治疗,并维持了严格的完全反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号